Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population

Vaccine

Volumn 29, Issue 44, 2011, Pages 7644-7650

  Castañeda Orjuela, Carlos ^a   Alvis Guzmán, Nelson ^a   Paternina, Ángel José ^a,b   De la Hoz Restrepo, Fernando ^a  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^b UNIVERSIDAD DE CARTAGENA   (Colombia)

Author keywords

Aged; Colombia; Cost benefit analysis; Streptococcus pneumoniae; Vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADULT; AGED; ARTICLE; COLOMBIA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MENINGITIS; PNEUMOCOCCAL MENINGITIS; PNEUMONIA; POPULATION RESEARCH; PRIORITY JOURNAL; PUBLIC HEALTH; SENSITIVITY ANALYSIS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

AGED; AGED, 80 AND OVER; COLOMBIA; COMMUNITY-ACQUIRED INFECTIONS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MENINGITIS, BACTERIAL; MIDDLE AGED; MODELS, STATISTICAL; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA, BACTERIAL;

EID: 80053577129     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.006     Document Type: Article

References (46)

1. Fedson D.S., Scott J.A. The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine 1999, 17(July (Suppl. 1)):S11-S18.
2. Robinson K.A., Baughman W., Rothrock G., Barrett N.L., Pass M., Lexau C., et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA 2001, 285(April (13)):1729-1735.
3. Ortqvist A., Hedlund J., Kalin M. Streptococcus pneumoniae: epidemiology, risk factors, and clinical features. Semin Respir Crit Care Med 2005, 26(December (6)):563-574.
4. Monto A.S. Acute respiratory infection in children of developing countries: challenge of the 1990s. Rev Infect Dis 1989, 11(May-June (3)):498-505.
5. Burman L.A., Norrby R., Trollfors B. Invasive pneumococcal infections: incidence, predisposing factors, and prognosis. Rev Infect Dis 1985, 7(March-April (2)):133-142.
6. Marrie T.J., Durant H., Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis 1989, 11(July-August (4)):586-599.
7. World Health Organization. Estimates of disease burden and cost-effectiveness. Geneva; 2008 [cited 2010 junio]. Available from: http://www.who.int/immunization_monitoring/burden/estimates_burden/en/index.html.
8. DANE. Cuadro 5. Defunciones, por grupos de edad y sexo, según lista de causas agrupadas 6/67 CIE-1 de OPS. Año 2007. Bogota, D.C.: DANE; 2007 [cited 2011 May]. Available from: http://www.dane.gov.co/daneweb_V09/index.php%3Foption=com_content%26view=article%26id=205%26Itemid=119.
9. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997;46(April (RR-8)):1-24.
10. Bogaert D., Hermans P.W., Adrian P.V., Rumke H.C., de Groot R. Pneumococcal vaccines: an update on current strategies. Vaccine 2004, 22(June (17-18)):2209-2220.
11. NHS Pneumococcal vaccine for older people 2004, Department of Health, London, UK. NHS (Ed.).
12. Dhankhar P., Grabenstein J.D., O'Brien M.A., Dasbach E.J. Cost-effectiveness of stockpiling 23-valent pneumococcal polysaccharide vaccine to prevent secondary pneumococcal infections among a high-risk population in the United States during an influenza pandemic. Clin Ther 2010, 32(August (8)):1501-1516.
13. Watson L., Wilson B.J., Waugh N. Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. Vaccine 2002, 20(May (17-18)):2166-2173.
14. Moore R.A., Wiffen P.J., Lipsky B.A. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam Pract 2000, 1:1.
15. Conaty S., Watson L., Dinnes J., Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine 2004, 22(August (23-24)):3214-3224.
16. Melegaro A., Edmunds W.J. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol 2004, 19(4):353-363.
17. Moberley S.A., Holden J., Tatham D.P., Andrews R.M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008, 1:CD000422.
18. De Graeve D., Lombaert G., Goossens H. Cost-effectiveness analysis of pneumococcal vaccination of adults and elderly persons in Belgium. Pharmacoeconomics 2000, 17(June (6)):591-601.
19. Castaneda-Orjuela C., Alvis-Guzman N., de la Hoz-Restrepo F. The impact of pneumococcal disease on adults living in Bogota, Colombia, 2008. Rev Salud Publica (Bogota) 2010, 12(February (1)):38-50.
20. DANE. Proyecciones de Población Municipales. Bogotá, D.C.: DANE; 2009 [2009 Feb 23]. Available from: http://www.dane.gov.co/index.php%3Foption=com_content%26task=category%26sectionid=16%26id=497%26Itemid=995.
21. PROFAMILIA. Encuesta Nacional de Demografia y Salud Bogota D.C.; 2005.
22. Matute A.J., Brouwer W.P., Hak E., Delgado E., Alonso E., Hoepelman I.M. Aetiology and resistance patterns of community-acquired pneumonia in Leon, Nicaragua. Int J Antimicrob Agents 2006, 28(November (5)):423-427.
23. Diaz A., Vera C., Santamarina J., Izarduy L., Bagnesco R., Grinspon S., et al. Neumonía adquirida en la comunidad en acncianos que requieren internación.Cuadro clínico y pronóstico. Medicina (Arg) 1999, 59(6):731-738.
24. Szot J. Mortalidad por enfermedades respiratorias en Chile durante 1999. Rev Chil Enferm Respir 2003, 19(1):8-14.
25. Dickinson F.O., Pérez A.E. Meningoencefalitis bacterianas en Cuba. Rev Cubana Hig Epidemiol 2001, 39(2):86-94.
26. Dickinson Meneses F., Pérez Rodríguez A. Meningoencefalitis bacterianas en el adulto mayor cubano 1998-2000. Geriátrika 2002, 18(6):32-40.
27. Gomes I., Lucena R., Melo A. Clinical and laboratory characteristics of pyogenic meningitis in adults. Arq Neuropsiquiatr 1997, 55(September (3B)):584-587.
28. Rossoni A.M., Dalla Costa L.M., Berto D.B., Farah S.S., Gelain M., Brandileone M.C., et al. Acute bacterial meningitis caused by Streptococcus pneumoniae resistant to the antimicrobian agents and their serotypes. Arq Neuropsiquiatr 2008, 66(September (3A)):509-515.
29. Ogilvie I., Khoury A.E., Cui Y., Dasbach E., Grabenstein J.D., Goetghebeur M. Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. Vaccine 2009, 27(August (36)):4891-4904.
30. WHO Commission on Macroeconomics and Health. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva; 2001.
31. Willems J.S. Cost effectiveness and cost benefit of vaccination against pneumococcal pneumonia: implications for clinical practice. Infect Control 1982, 3(July-August (4)):299-302.
32. Willems J.S., Sanders C.R., Riddiough M.A., Bell J.C. Cost effectiveness of vaccination against pneumococcal pneumonia. N Engl J Med 1980, 303(September (10)):553-559.
33. Ament A., Baltussen R., Duru G., Rigaud-Bully C., de Graeve D., Ortqvist A., et al. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin Infect Dis 2000, 31(August (2)):444-450.
34. Levy E. Cost effectiveness of pneumococcal vaccine (author's transl). Rev Epidemiol Sante Publique 1981, 29(2):133-153.
35. Patrick K.M., Woolley F.R. A cost-benefit analysis of immunization for pneumococcal pneumonia. JAMA 1981, 245(February (5)):473-477.
36. Plans P. Cost-effectiveness of 23-valent antipneumococcical vaccination in Catalonia (Spain). Gac Sanit 2002, 16(September-October (5)):392-400.
37. Ruiz-Gonzalez A., Falguera M., Nogues A., Rubio-Caballero M. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med 1999, 106(April (4)):385-390.
38. Mandell L.A., Wunderink R.G., Anzueto A., Bartlett J.G., Campbell G.D., Dean N.C., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(March (Suppl. 2)):S27-S72.
39. Brown P.D., Lerner S.A. Community-acquired pneumonia. Lancet 1998, 352(October (9136)):1295-1302.
40. Jackson M.L., Neuzil K.M., Thompson W.W., Shay D.K., Yu O., Hanson C.A., et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 2004, 39(December (11)):1642-1650.
41. World Health Organization, 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec 2008;83(October (42)):373-84.
42. Huss A., Pippa Scott P., Stuck A.E., Trotter C., Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. Can Med Assoc J 2009, 180(January (1)):48-58.
43. Butler J.C., Breiman R.F., Campbell J.F., Lipman H.B., Broome C.V., Facklam R.R. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993, 270(October (15)):1826-1831.
44. Mangtani P., Cutts F., Hall A.J. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis 2003, 3(February (2)):71-78.
45. Zhogolev S.D., Ogarkov P.I., Mel'nichenko P.I. The prophylaxis of nonhospital pneumonia using 23-valent pneumococcus vaccine in the military collectives. Voen Med Zh 2004, 325(December (12)):35-43. 96.
46. Standaert B., Parez N., Tehard B., Colin X., Detournay B. Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France. Appl Health Economics Health Policy 2008, 6(4):199-216.